Products for Research Use Only

Bobcat339

CAT: 0804-HY-111558-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-111558-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bobcat339 is a potent and selective cytosine-based inhibitor of TET enzyme, with IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription[1].
CAS Number
2280037-51-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
DNA Methyltransferase; TET Protein
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bobcat339.html
Purity
99.44
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC1=NC(N(C2=CC=CC(C3=CC=CC=C3)=C2)C=C1Cl)=O
Molecular Formula
C16H12ClN3O
Molecular Weight
297.74
Precautions
H302, H315, H319, H335
References & Citations
[1]Chua GNL, et, al. Cytosine-Based TET Enzyme Inhibitors. ACS Med Chem Lett. 2019 Jan 31; 10 (2) : 180-185.|[2]Weirath NA, et al. Small Molecule Inhibitors of TET Dioxygenases: Bobcat339 Activity Is Mediated by Contaminating Copper (II) . ACS Med Chem Lett. 2022 Apr 21;13 (5) :792-798.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
TET1; TET2
Citation 01
Aquaculture. 2023: 739234.|Br J Pharmacol. 2024 Oct;181 (20) :3886-3907.|Brain Sci. 2023 Apr 10;13 (4) :644.|EMBO Mol Med. 2025 Oct;17 (10) :2809-2826.|Eur J Pharmacol. 2024 Aug 23:176931.|J Exp Clin Cancer Res. 2025 Jul 15;44 (1) :206.|Research Square Print. 2023 Mar 14.|Research Square Print. November 29th, 2022.|Bioelectrochemistry. 2023 Aug:152:108433.|Cancers (Basel) . 2022 Jun 16;14 (12) :2983.|Cell Death Dis. 2024 Jun 1;15 (6) :387.|Clin Epigenetics. 2024 Oct 2;16 (1) :136.|Clin Sci. 2023 Aug 31;137 (16) :1265-1283.|Environ Sci Technol. 2021 Mar 2;55 (5) :3144-3155.|J Clin Invest. 2023 Oct 16;133 (20) :e170173.|J Pharm Biomed Anal. 2021 Sep 5:203:114228.|Mol Pain. 2022 Apr;18:17448069221143671.|Nat Metab. 2025 Jul;7 (7) :1344-1357.|Neuropharmacology. 2024 Feb 15:244:109799.|Sci Total Environ. 2024 Apr 1:919:170905.|Theranostics. 2021 Jun 11;11 (16) :7640-7657.